Leerink Partnrs Issues Positive Forecast for INSP Earnings

Inspire Medical Systems, Inc. (NYSE:INSP) – Equities research analysts at Leerink Partnrs increased their Q4 2024 EPS estimates for shares of Inspire Medical Systems in a research note issued on Monday, November 4th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of $0.77 for the quarter, up from their prior forecast of $0.72. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $0.75 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems’ Q4 2025 earnings at $1.12 EPS and FY2028 earnings at $5.77 EPS.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Monday, November 4th. The company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.54. The company had revenue of $203.20 million during the quarter, compared to analysts’ expectations of $197.59 million. Inspire Medical Systems had a return on equity of 1.03% and a net margin of 0.85%. The company’s revenue for the quarter was up 32.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.29) earnings per share.

INSP has been the subject of a number of other reports. Stifel Nicolaus reaffirmed a “hold” rating and issued a $200.00 price target (up from $170.00) on shares of Inspire Medical Systems in a research note on Tuesday. KeyCorp cut their target price on Inspire Medical Systems from $278.00 to $236.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Leerink Partners lifted their price target on Inspire Medical Systems from $167.00 to $197.00 and gave the company a “market perform” rating in a research report on Tuesday, September 10th. Robert W. Baird upped their price objective on Inspire Medical Systems from $240.00 to $252.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Truist Financial reaffirmed a “buy” rating and set a $240.00 target price (up previously from $217.00) on shares of Inspire Medical Systems in a research note on Monday, September 30th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Inspire Medical Systems presently has an average rating of “Moderate Buy” and a consensus target price of $227.75.

Inspire Medical Systems Stock Up 3.3 %

Shares of INSP opened at $199.01 on Wednesday. The firm has a market capitalization of $5.93 billion, a PE ratio of 185.99 and a beta of 1.36. The firm has a 50-day moving average price of $201.37 and a 200 day moving average price of $179.72. Inspire Medical Systems has a 52-week low of $123.00 and a 52-week high of $257.40.

Insider Activity at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 800 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $220.00, for a total transaction of $176,000.00. Following the sale, the director now owns 23,140 shares in the company, valued at approximately $5,090,800. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Shawn Mccormick sold 800 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $220.00, for a total value of $176,000.00. Following the completion of the transaction, the director now owns 23,140 shares of the company’s stock, valued at approximately $5,090,800. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Randy Ban sold 4,861 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $188.55, for a total transaction of $916,541.55. Following the sale, the insider now directly owns 3,056 shares in the company, valued at approximately $576,208.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,692 shares of company stock worth $1,099,207 in the last quarter. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Inspire Medical Systems

Several hedge funds have recently bought and sold shares of the business. SouthState Corp acquired a new position in shares of Inspire Medical Systems in the 2nd quarter valued at about $27,000. Farther Finance Advisors LLC grew its position in Inspire Medical Systems by 1,158.3% during the third quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock valued at $32,000 after purchasing an additional 139 shares in the last quarter. GAMMA Investing LLC increased its stake in Inspire Medical Systems by 559.3% in the 3rd quarter. GAMMA Investing LLC now owns 178 shares of the company’s stock valued at $38,000 after buying an additional 151 shares during the period. Quarry LP increased its stake in Inspire Medical Systems by 105.4% in the 2nd quarter. Quarry LP now owns 343 shares of the company’s stock valued at $46,000 after buying an additional 176 shares during the period. Finally, Daiwa Securities Group Inc. purchased a new stake in Inspire Medical Systems in the 2nd quarter worth approximately $53,000. 94.91% of the stock is owned by hedge funds and other institutional investors.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.